This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Botteman MF, Meijboom M, Kaura S, Durand-Zaleski I.Cost effectiveness of zoledronic acid for the prevention of skeletal related events in prostate cancer patients with bone metastases in France. 2009 Genitourinary Cancers Symposium: abstr. 206, 26 Feb 2009. Available from: URL: http://www.asco.org
Rights and permissions
About this article
Cite this article
Zoledronic acid worth it for preventing SREs in France. Pharmacoecon. Outcomes News 574, 4 (2009). https://doi.org/10.2165/00151234-200905740-00010
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905740-00010